Cargando…
Advances and controversies in the management of early stage non-small cell lung cancer
Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. The landmark Lung Cancer Study Group trial in 1995 established lobectomy as the minimum intervention necessary for the management of early-stage non-small cell lung cancer, as it was associated with lo...
Autores principales: | Cilleruelo-Ramos, Angel, Cladellas-Gutiérrez, Esther, de la Pinta, Carolina, Quintana-Cortés, Laura, Sosa-Fajardo, Paloma, Couñago, Felipe, Mielgo-Rubio, Xabier, Trujillo-Reyes, Juan Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716990/ https://www.ncbi.nlm.nih.gov/pubmed/35070733 http://dx.doi.org/10.5306/wjco.v12.i12.1089 |
Ejemplares similares
-
Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
por: Sereno, María, et al.
Publicado: (2021) -
Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2020) -
Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
por: Sotelo, Miguel J, et al.
Publicado: (2021) -
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021) -
Tsunami of immunotherapy reaches mesothelioma
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2022)